Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma.
Thirty-five patients with advanced malignant melanoma were treated with 4'-epi-doxorubicin iv once every 3 weeks. Most patients had not received prior chemotherapy and had good performance status. Three partial remissions and three minor regressions were observed. All patients experienced myelosuppression, but other toxic effects were minimal. 4'-Epi-doxorubicin has limited therapeutic activity in this disease.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004341:Drug Evaluation; D015251:Epirubicin; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors
D000970:Antineoplastic Agents; D015251:Epirubicin; D004317:Doxorubicin